| Literature DB >> 30632263 |
Xiao-Xia Pang1,2, Shun-Da Luo3, Ting Zhang2, Feng Shi1,2, Chun-Fang Wang4, Xing-Hong Chen2, Yu-Xia Wei2, Li Qin2, Jing-Xi Wei2, Xiao-Qiong Luo2, Jun-Li Wang2.
Abstract
Interleukin-27 (IL-27) gene polymorphisms are linked to infectious disease susceptibility and IL-27 plasma level is associated with HIV infection. Therefore, we aimed to investigate the association between IL-27 polymorphisms and susceptibility to HIV infection and disease progression. A total of 300 patients with HIV infection (48 long-term nonprogressors and 252 typical progressors) and 300 healthy controls were genotyped for three IL-27 polymorphisms, rs17855750, rs181206, rs40837 which were performed by using multiple single nucleotide primer extension technique. Significant association was found between IL-27 rs40837 polymorphisms with susceptibility to HIV infection (AG vs AA: adjusted OR = 1.60, 95% CI, 1.11-2.30, P = 0.012; AG+GG vs AA: adjusted OR = 1.44, 95% CI, 1.02-2.03, P = 0.038) and disease progression (LTNP: AG vs AA: adjusted OR = 2.33, 95% CI, 1.13-4.80, P = 0.021; TP: AG vs AA: adjusted OR = 1.50, 95% CI, 1.04-2.24, P = 0.030). Serum IL-27 levels were significantly lower in cases compared to controls (P < 0.001). There were lower serum IL-27 levels in TPs than in LTNPs (P < 0.001). We further found that LTNPs with rs40837 AG or GG genotype had lower serum IL-27 levels than with AA genotype (P < 0.05). The CD4+ T counts in cases were significantly lower than controls (P < 0.001). In contrast, individuals with rs40837 AG genotype had lower CD4+ T counts than with AA genotype in cases (P < 0.05). In addition, CD4+ T counts in TPs were significantly lower than LTNPs (P < 0.001). IL-27 rs40837 polymorphism might influence the susceptibility to HIV infection and disease progression probably by regulating the level of serum IL-27 or the quantity of CD4+ T.Entities:
Keywords: HIV infection; IL-27; disease progression; polymorphism
Mesh:
Substances:
Year: 2019 PMID: 30632263 PMCID: PMC6433771 DOI: 10.1111/jcmm.14067
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
The primer sequences used for detecting IL‐27N SNPs
| SNP ID | PCR primers |
|---|---|
| rs17855750 | F:5′‐ CTGGGGGGCAAGGTCTGTTAGT‐3′ |
| R: 5′‐ TCAAGCTGGTGTCTGGGGATTC‐3′ | |
| EF:5′‐ TTTTTTTTTTTTTTTTTTTTTTTCATCTCGCCAGGAAGCTGCTC‐3′ | |
| rs181206 | F: 5′‐ CAGCTGCATCCTCTCCATGTTG‐3′ |
| R: 5′‐ GCTGAGGTGGGGGAAGAGCTAC‐3′ | |
| EF: 5′‐ TTTTGGTCCCCAGCCCTCCCAGC‐3′ | |
| rs40837 | F: 5′‐ GAGGACCAGAGGGGCTTTCAGT‐3′ |
| R: 5′‐ CCCTGATCGGTGGCTTCTTAGC‐3′ | |
| EF: 5′‐ CCAGCCCCCTGCCCCAGGC‐3′ |
Demographics and clinical parameters of HIV‐infected patients and controls
| Variables | HIV‐infected patients (n = 300) | Healthy controls (n = 300) |
|
|---|---|---|---|
| Age (y), mean ± SD | 48.7 ± 17.0 | 47.6 ± 12.2 | 0.345 |
| Gender n (%) | |||
| Male | 180 (60.0%) | 174 (58.0%) | 0.618 |
| Female | 120 (40.0%) | 126 (42.0%) | |
| Disease progression n (%) | |||
| LTNP | 48 (16.0%) | ||
| TP | 252 (84.0%) | ||
| IL‐27 (pg/mL), median | 189.25 (75.60‐286.30) | 265.80 (229.00‐389.90) | <0.001 |
| HIV viral road (copies/mL), median | 510 23.50 (214‐111025) | NA | |
| CD4+T count (cells/mm3), median | 75.00 (18‐693) | 789.50 (457‐2106) | <0.001 |
| CD8+T count (cells/mm3), median | 426.50 (27‐2161) | 416.50 (155‐1696) | 0.708 |
NA, not available.
Demographics and clinical parameters of LTNP and TP
| Variable | LTNP group (n = 48) | TP group (n = 252) |
|
|---|---|---|---|
| Age (y), mean ± SD | 49.0 ± 14.8 | 47.3 ± 11.6 | 0.450 |
| Gender n (%) | |||
| Male | 30 (62.5%) | 150 (59.5%) | 0.149 |
| Female | 18 (37.5%) | 102 (40.5%) | |
| IL‐27 (pg/mL), median | 242.45 (185.00‐286.30) | 186.05 (75.60‐254.00) | <0.001 |
| HIV viral road (copies/mL), median | 512.50 (214‐2105) | 592 55.00 (1230‐111025) | <0.001 |
| CD4+T count (cells/mm3), median | 530.50 (506‐693) | 46.50 (18‐390) | <0.001 |
| CD8+T count (cells/mm3), median | 453.00 (327‐1078) | 407.00 (27‐2161) | 0.038 |
Genotypes and allele frequencies of IL‐27 in HIV‐infected patients and controls
| Polymorphism | Cases n = 300 (%) | Controls n = 300 (%) | OR (95% CI) |
|
|---|---|---|---|---|
| rs17855750 | ||||
| AA | 223 (74.3) | 204 (68.0) | 1.00 (reference) | |
| AC | 70 (23.3) | 90 (30.0) | 0.72 (0.50‐1.04) | 0.083 |
| CC | 7 (2.3) | 6 (2.0) | 0.98 (0.32‐3.00) | 0.970 |
| AC+CC | 77 (25.6) | 96 (32.0) | 0.74 (0.51‐1.06) | 0.098 |
| A | 516 (86.0) | 498 (83.0) | 1.00 (reference) | |
| C | 84 (14.0) | 102 (17.0) | 0.80 (0.58‐1.09) | 0.151 |
| rs181206 | ||||
| AA | 165 (55.0) | 170 (56.7) | 1.00 (reference) | |
| AG | 106 (35.3) | 106 (35.3) | 1.01 (0.71‐1.43) | 0.968 |
| GG | 29 (9.7) | 24 (8.0) | 1.45 (0.81‐2.60) | 0.216 |
| AG+GG | 135 (45.0) | 130 (43.3) | 1.09 (0.78‐1.51) | 0.624 |
| A | 436 (72.7) | 446 (74.3) | 1.00 (reference) | |
| G | 164 (27.3) | 154 (25.7) | 1.09 (0.84‐1.41) | 0.513 |
| rs40837 | ||||
| AA | 93 (31.0) | 117 (39.0) | 1.00 (reference) | |
| AG | 162 (54.0) | 132 (44.0) | 1.60 (1.11‐2.30) |
|
| GG | 45 (15.0) | 51 (17.0) | 1.05 (0.64‐1.72) | 0.856 |
| AG+GG | 207 (69.0) | 183 (61.0) | 1.44 (1.02‐2.03) |
|
| A | 348 (58.0) | 366 (61.0) | 1.00 (reference) | |
| G | 252 (42.0) | 234 (39.0) | 1.13 (0.90‐1.45) | 0.290 |
Sum of the genotype frequencies may not be 100% due to the rounding at one decimal positions.
OR, odds ratio; 95% CI, 95% confidence interval.
Adjusted by age and gender.
Significance of bold values: Our results have demonstrated that rs40837 polymorphss of IL‐27 were significangtly associated with susceptibility to HIV infection, individuals carrying AG and AG+GG of rs40837 had a increased risk of infecting HIV.
Genotypes and allele frequencies of IL‐27 in LTNPs and TPs
| Polymorphism | Controls n = 300 (%) | LTNP n = 48 (%) | TP n = 252 (%) | LTNP vs Controls OR (95% CI) |
| TP vs Controls OR (95% CI) |
|
|---|---|---|---|---|---|---|---|
| rs17855750 | |||||||
| AA | 204 (68.0) | 35 (73.0) | 188 (74.6) | 1.00 (reference) | 1.00 (reference) | ||
| AC | 90 (30.0) | 10 (20.8) | 60 (23.8) | 0.70 (0.33‐1.48) | 0.343 | 0.72 (0.49‐1.07) | 0.106 |
| CC | 6 (2.0) | 3 (6.3) | 4 (1.6) | 2.85 (0.67‐12.11) | 0.156 | 0.62 (0.17‐2.27) | 0.470 |
| AC+CC | 96 (32.0) | 13 (27.1) | 64 (25.4) | 0.84 (0.42‐1.68) | 0.627 | 1.39 (0.95‐2.04) | 0.088 |
| A | 498 (83.0) | 80 (83.3) | 436 (86.5) | 1.00 (reference) | 1.00 (reference) | ||
| C | 102 (17.0) | 16 (16.7) | 68 (13.5) | 0.98 (0.55‐1.74) | 0.936 | 0.76 (0.55‐1.06) | 0.108 |
| rs181206 | |||||||
| AA | 170 (56.7) | 24 (50.0) | 138 (54.8) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 106 (35.3) | 16 (33.3) | 90 (35.7) | 1.01 (0.51‐2.00) | 0.985 | 1.00 (0.69‐1.45) | 0.998 |
| GG | 24 (8.0) | 8 (16.7) | 24 (9.5) | 2.26 (0.90‐5.68) | 0.083 | 1.23 (0.66‐2.30) | 0.510 |
| AG+GG | 130 (43.3) | 24 (50.0) | 114 (45.2) | 1.23 (0.66‐2.29) | 0.508 | 1.04 (0.74‐1.47) | 0.813 |
| A | 446 (74.3) | 64 (66.7) | 366 (72.6) | 1.00 (reference) | 1.00 (reference) | ||
| G | 154 (25.7) | 32 (33.3) | 138 (27.4) | 1.45 (0.91‐2.30) | 0.115 | 1.09 (0.84‐1.43) | 0.520 |
| rs40837 | |||||||
| AA | 117 (39.0) | 12 (25.0) | 81 (32.1) | 1.00 (reference) | 1.00 (reference) | ||
| AG | 132 (44.0) | 30 (62.5) | 132 (52.4) | 2.33 (1.13‐4.80) |
| 1.53 (1.04‐2.24) |
|
| GG | 51 (17.0) | 6 (12.5) | 39 (15.5) | 1.17 (0.41‐3.33) | 0.762 | 1.07 (0.64‐1.79) | 0.805 |
| AG+GG | 183 (61.0) | 36 (75.0) | 171 (67.9) | 2.00 (1.00‐4.03) | 0.051 | 0.72 (0.50‐1.03) | 0.071 |
| A | 366 (61.0) | 54 (56.3) | 294 (58.3) | 1.00 (reference) | 1.00 (reference) | ||
| G | 234 (39.0) | 42 (43.8) | 210 (41.7) | 1.22 (0.79‐1.88) | 0.377 | 1.12 (0.88‐1.42) | 0.368 |
Sum of the genotype frequencies may not be 100% due to the rounding at one decimal positions.
OR, odds ratio; 95% CI, 95% confidence interval.
Adjusted by age and gender.
Significance of bold values: In accordance with our further study, we found that IL‐27 rs40837 polymorphisms may be related to disease progression of HIV infection. When homozygotes of major allele was taken as references, the heterozygote AG of rs40837 showed high OR in the LTNP group and low OR in the TP group. These observations suggest that the majority of patients carrying rs40837 heterozygote stay in the LTNP period compared with TP period.
Figure 1ELISA determination of IL‐27 expression. A, Serum IL‐27 levels in HIV‐infected patients and controls. B, Serum IL‐27 levels in LTNPs and TPs. C, Serum IL‐27 levels in LTNPs with different genotypes of rs40837 (AA, AG, GG). Data were presented as a box plot with 2.5‐97.5 percentile. Statistical tests were performed using Mann‐Whitney U test
Figure 2CD4+T and CD8+T count. A, CD4+T counts in HIV‐infected patients and controls. B, CD4+T counts in HIV‐infected patients with different genotypes of rs40837 (AA, AG, GG). C, CD4+T counts in LTNPs and TPs. D, CD8+T counts in LTNPs and TPs. Data were presented as a box plot with 2.5‐97.5 percentile. Statistical tests were performed using Mann‐Whitney U test
Figure 3Correlation analysis. A, Serum IL‐27 concentration and HIV viral road. B, Serum IL‐27 concentration and CD4+T counts. C, Serum IL‐27 concentration and CD8+T counts. D, HIV viral road and CD4+T counts. E, HIV viral road and CD8+T counts. F, CD4+T counts and CD8+T counts